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Steroid-refractory acute graft-versus-host disease (aGVHD) remains an important cause of morbidity and
mortality after allogeneic stem cell transplantation (SCT). A protocol on the management of aGVHD was
introduced in our center that incorporated a prospective study on combination therapy with inolimomab
(anti-IL-2Ra) and etanercept (antietumor necrosis factor-a) for steroid-refractory aGVHD. We evaluated the
efﬁcacy and safety in 21 consecutively treated patients. The patients had developed refractory aGVHD after
SCT (n ¼ 16) or donor lymphocyte infusion (n ¼ 5), and aGVHD was classiﬁed as severe in all patients, mostly
due to gastrointestinal involvement stages 2 to 4. No drug-related side effects were observed apart from the
infections expected to occur in these severely immunocompromised patients. Overall response at day 28 of
second-line therapy was 48% (10/21), with 6 and 4 patients achieving a complete and partial response,
respectively. Eventually, 19 patients died (90%), with early mortality (<6 months) predominantly resulting
from refractory aGVHD and secondary infections and late mortality resulting from relapse of the underlying
disease. With a median follow-up of 55 days, the estimated rates of 6-month and 2-year overall survival were
dismal, 29% and 10%, respectively. In conclusion, the combination of inolimomab and etanercept for steroid-
refractory aGVHD failed to improve the dismal prognosis of severe steroid-refractory aGVHD.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION pathogenesis. Etanercept is a tumor necrosis factor-
Allogeneic hematopoietic stem cell transplantation (SCT)
constitutes a potentially curative approach for hematologic
malignancies, but its success can be reduced by the
occurrence of acute graft-versus-host disease (aGVHD) [1].
First-line treatment with high-dose corticosteroids (ie,
methylprednisolone 2 mg/kg) is currently the standard for
patients developing aGVHD grade  II, achieving complete
responses (CRs) in 40% to 50% [2,3]. However, the prognosis of
patients with aGVHD who are refractory to this therapy is
poor, especially when it concerns grades III to IV (severe)
aGVHD due to gastrointestinal (GI) GVHD [2,4]. Several
treatmentmodalities have been used for second-line therapy,
but the results have generally been disappointing, with long-
term overall survival (OS) rates of approximately 20% to 30%
at 3 years [5]. Therefore, there is no consensus onwhat should
be considered the most efﬁcacious second-line therapy [3].
In the past our center used high-dose methylpredniso-
lone, 1000 mg for 3 days, for refractory aGVHD with poor
results, especially in those with severe aGVHD due to GI
involvement [6]. Therefore, we adopted a new protocol that
incorporated a prospective study of the combination of
inolimomab and etanercept. The choice was based on pre-
vious reports on the efﬁcacy of inolimomab and etanercept
as single agents and the theoretical advantage of combining
2 drugs that target key pathways involved in GVHDdgments on page 182.
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y for Blood andMarrow Transplantation.aereceptor fusion protein that scavenges tumor necrosis
factor-a and has shown promising results in ﬁrst- and
second-line therapy for aGVHD [7,8]. Inolimomab is a
monoclonal antibody targeting the IL-2 receptor subunit a
(CD25) that predominantly inhibits activated alloreactive
Tcells. Several studies have shown encouraging results in the
treatment of steroid-refractory aGVHD with inolimomab
[9,10]. In this study we evaluated the efﬁcacy and safety of
the combination therapy and expected higher response rates.
METHODS
Treatment Protocol
We introduced a protocol in February 2010 for managing aGVHD that
incorporated a prospective open-label study on the combination of
inolimomab and etanercept for the treatment of aGVHD refractory to
corticosteroids. Approval of the local ethics committee (CMO Regio
Arnhem-Nijmegen) was obtained before implementation of the protocol
and start of the study. Patients signed informed consent before partici-
pating in the protocol.
aGVHD was scored according to the consensus criteria of Przepiorka
et al. [11], and GVHD was preferably conﬁrmed by histologic examination of
biopsies taken from involved sites. The initial treatment of aGVHD
grades  II consisted of prednisolone (2 mg/kg) in combination with
cyclosporine A or mycophenolate mofetil. Steroid-refractory aGVHD was
deﬁned as failure to achieve at least a partial response (PR) 5 days after the
initiation of prednisolone, no further improvement on day 10 compared
with day 5, or a recurrence of aGVHD after tapering of corticosteroids.
Second-line treatment with inolimomab and etanercept started when
refractory aGVHD was established.
Etanercept (Enbrel; Wyeth Pharmaceuticals bv, Hoofddorp, The
Netherlands) was given subcutaneously twice weekly at a dose of 25 mg for
4 weeks. Inolimomab (Leukotac; EUSA Pharma, Limonest, France) was
administered intravenously with a dose of .3 mg/kg daily from days 1 to 8
and a dose of .4 mg/kg every other day from days 9 to 28. Primary endpoints
were the overall response rate on day 28 of second-line therapy and the
6-month estimated OS [3,12-14]. Our goal was to achieve an overall response
rate of at least 50% and a 6-month OS rate of at least 30%. Secondary end-
points were response on day 56, long-term OS, and safety and tolerability.
Table 1
Characteristics of Patients (N ¼ 21) Receiving Second-Line Therapy with
Inolimomab and Etanercept
Characteristics Value
Median age, yr (range) 54 (24-66)
Male/female 11/10
Donor type, n (%)
MRD 11 (52%)
MUD 7 (33%)
MMUD 3 (15%)
Diagnosis, n (%)
AML/MDS 12 (57%)
NHL/CLL 4 (19%)
Other 5 (24%)
Conditioning, n (%)
NMA/RI 8 (38%)
MA 13 (62%)
T cell depletion, n (%)
Yes
In vivo (ATG or alemtuzumab) 8 (38%)
Ex vivo 16 (76%)
No 4 (19%)
Stem cell source peripheral blood, n (%) 21 (100%)
GVHD setting, n (%)
Post-SCT 16 (76%)
Post-DLI 5 (24%)
Dose of DLI (n ¼ 5) CD3þ cells  108/kg .01
aGVHD, n (%)
Skin 17 (81%)
Lower GI 19 (90%)
Upper GI 6 (29%)
Liver 7 (33%)
Acute GI GVHD, n (%) (n ¼ 19)
Stage 1 1 (5%)
Stage 2-4 18 (95%)
MRD indicates matched related donor; MUD, matched unrelated donor;
MMUD, mismatched unrelated donor; AML, acute myeloid leukemia; MDS,
myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; CLL, chronic
lymphocytic leukemia; NMA, nonmyeloablative; RI, reduced intensity; MA,
myeloablative; ATG, antithymocyte globulin.
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and Candida in case of colonization. All patients were monitored twice
weekly for Epstein-Barr virus (EBV) and cytomegalovirus (CMV). EBV reac-
tivation, deﬁned as an EBV PCR  log 3, was preemptively treated with 4
doses of rituximab (375 mg/m2). In case of CMV reactivation patients
received ganciclovir, valganciclovir, or foscarnet. Galactomannanwas tested
twice weekly, and a high-resolution computed tomography was ordered
when invasive mold disease was suspected followed by bronchoalveolar
lavage when applicable. Possible, probable, and proven invasive mold dis-
ease were treated with voriconazole.
Deﬁnitions of Outcome
CR was deﬁned as resolution of all signs and symptoms of aGVHD. A PR
was deﬁned as an improvement of 1 stage in 1 or more organs without
progression or newly developed aGVHD in another organ. Mixed response
was considered an improvement in at least 1 organ with progression or
newly developed aGVHD in another organ. No response was deﬁned as
absence of improvement. Progression was deﬁned as worsening by 1 or
more stages without improvement in any involved organ [12]. All adverse
events observed during the treatment were recorded and scored according
the Common Toxicity Criteria version 4.
Statistical Analysis
We used descriptive statistics for the study group characteristics and
outcome of therapy. Univariable analyses for risk factors for treatment
response and OS at 6 months were performed by Fisher’s exact test and chi-
square test. Logistic regression analysis was used to perform multivariable
analysis for risk factors with P  .2 in univariable analysis. OS was estimated
by the Kaplan-Meier method. SPSS was used for the statistical analysis.
P < .05 was considered to be statistically signiﬁcant (SPSS version 22.0.01;
IBM, Armonk, NY).
RESULTS
Patient Characteristics
From February 2010 to February 2014, 185 patients
received an allogeneic SCT with a follow-up of at least
6 months. Seventy-one patients developed histologically
conﬁrmed aGVHD grade  II (38%: post-SCT n ¼ 59 [32%],
postedonor lymphocyte infusion [DLI] n ¼ 12 [6%]), and
severe aGVHD occurred in 39 patients (21%). All patients
were treated initially with prednisolone 2 mg/kg, but aGVHD
proved to be steroid refractory in 25 of 71 cases (35%), and all
these cases concerned grades III to IV aGVHD (25/39 [64%]).
Of these, 21 were treated with combination therapy. Four did
not receive this treatment, mostly because of a very poor
performance status deﬁned as a life expectancy of less than
28 days. Patient characteristics, conditioning regimens, and
graft characteristics of these 21 patients are summarized in
Table 1.
aGVHD and Response to Second-Line Therapy
All 21 patients had severe aGVHD at the start of second-
line treatment: 17 with grade III and 4 with grade IV. The
median time from SCT or DLI to the diagnosis of aGVHD was
37 days (range, 15 to 263). Seventeen patients had GVHD
involving the skin, 19 involving the gut, and 7 involving the
liver (Table 1). Hence, most patients had aGVHD involvement
of at least 2 organs (17/21 [81%]).
Start of second-line therapy was a median of 8 days
(range, 4 to 24) after start of corticosteroid therapy. The
median treatment duration was 25 days (range, 6 to 28). Of
the 21 patients 6 and 4 patients achieved a CR and PR,
respectively, bringing the overall response rate on day 28 to
48% (10/21). Steroids were not tapered at the time of starting
inolimomab and etanercept. In case of GVHD improvement,
deﬁned as at least a PR, prednisone was tapered in accor-
dance with the Seattle scheme for aGVHD, which means
tapering of .2 mg/kg prednisone every 5 days. Patients
also continued cyclosporine or mycophenolate mofetil.
When cyclosporine toxicity was suspected, the dosage ofcyclosporine was decreased on the treating physician’s
judgment. If there was no toxicity, cyclosporine was
continued during the treatment with etanercept and inoli-
momab. Three patients, who initially had achieved a
response, developed a ﬂare-up and received third-line ther-
apy consisting of mesenchymal stem cells, but without effect.
Hence, on day 56 the overall response rate was 33%, with 5
patients retaining a CR and 2 a PR.
Univariable analysis revealed several risk factors for
treatment response with P < .2, namely liver GVHD stages 2
to 4, albumin level < 25 g/L at diagnosis, disease category
acute myeloid leukemia, and GVHD setting post-DLI. Logistic
regression analysis with these 4 risk factors conﬁrmed a
statistically signiﬁcant impact of GVHD setting post-DLI
(P ¼ .01) and liver GVHD stages 2 to 4 (P ¼ .03) but only a
trend for low albumin (P ¼ .07). Disease category was no
longer statistically signiﬁcant (Table 2).aGVHD and DLI
Patients who suffered from steroid-refractory aGVHD that
had occurred post-DLI all died of GVHD despite the use of
inolimomab/etanercept. DLI had been given in a low dose
(range, .5 to 5  106 CD3þ T cells/kg). The indication for the
preemptive DLI in all these patients who had been trans-
planted with a partially T celledepleted graft was realization
of full donor chimerism and boosting of the graft-versus-
leukemia effect.
Table 2
Risk Factors for GVHD Treatment Response
Risk Factor GVHD Overall
Response Rate
P
(Univariable)
P
(Multivariable)
Age
50 yr 7/15 (47%) 1.0 d
<50 yr 3/6 (50%)
Gender
Male 7/11 (64%) .2 d
Female 3/10 (30%)
Diagnosis
AML/MDS 8/12 (67%) .1 .7
NHL/CLL 1/4 (25%)
Other 1/5 (20%)
Donor
MRD 7/11 (64%) .2 d
MMUD 3/10 (30%)
Serum albumin at
diagnosis
<25 g/L 1/6 (17%) .15 .07
25 g/L 9/15 (60%)
Skin GVHD stage 2-4
Yes 7/15 (47%) 1.0 d
No 3/6 (50%)
Liver GVHD stage 2-4
Yes 1/7 (14%) .06 .03
No 9/14 (64%)
Gut GVHD stage 3-4
Yes 7/13 (54%) .7 d
No 3/8 (38%)
GVHD setting
Post-SCT 10/16 (63%) .03 .01
Post-DLI 0/5 (0%)
Start second-line
therapy
7 days 4/11 (37%) .4 d
>7 days 6/10 (60%)
Table 3
Causes of Death
Causes of Death Number of
Patients
Refractory aGVHD (in combination with secondary
infections)
13
Relapse of underlying disease 3
Relapse of aGVHD 3
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After a median follow-up of 55 days (range,15 to 962), the
estimated rates of 6-month and 2-year OS were dismal, 29%
and 10%, respectively (Figure 1). Eventually, 19 patients died
(90%), with early mortality (<6 months) predominantly
resulting from refractory aGVHD and secondary infections
and late mortality (6 months) resulting from relapse of the
underlying disease. Of those achieving a CR, 2 patients sur-
vived and 4 died: 1 from relapsed aGVHD and 3 from relapse
of their hematologic malignancy (Table 3). In the analysis onFigure 1. Estimated rates of 6-month and 2-year OS.risk factors for survival at 6 months, only achieving a
response on therapy was signiﬁcant (0/11 [0%] versus 5/10
[50%], P ¼ .012).
Infections and Adverse Events
No infusion-related adverse events were observed that
were related to inolimomab and etanercept; however, in-
fectious complications occurred frequently. Thirteen patients
suffered from at least 1 infectious episode after the start of
the second-line therapy. Bacteremia was a frequent compli-
cation (7/21; 33%), with Enterococci and Staphylococcus
aureus as the main causative bacteria. Two patients both
developed a probable invasive mold disease, CMV infection
(1 progressing to CMV colitis), and adenovirus infection.
Three patients had an EBV infection during therapy, but post-
transplantation lymphoproliferative disease did not occur
because all 3 were successfully treated with rituximab.
Because of these infectious complications, some patients
stopped earlier with etanercept and inolimomab treatment.
DISCUSSION
The overall response rate for steroid-refractory aGVHD
was 48% after combination therapy with etanercept and
inolimomab, with 6 of 21 patients achieving a complete
response. These results were initially encouraging consid-
ering the fact that all patients suffered from severe aGVHD
and almost all had involvement of the GI tract. The combi-
nation treatment was well tolerated and proved to be safe
without the occurrence of infusion-related events. Never-
theless, rates of OS proved to be disappointing, with only 10%
of patients alive at last follow-up. Patients died either
because of treatment failure with ongoing GVHD, often
accompanied by infectious complications, or, after having
achieved a remission, because of relapse of the underlying
hematologic malignancy. Therefore, achieving even a com-
plete remission was no guarantee for long-term survival.
Although recognizing the limitations of the multivariable
analysis in this small cohort, several risk factors seemed to be
associated with a particularly poor prognosis and consisted
of stages 2 to 4 liver GVHD, GVHD post-DLI, and a low al-
bumin level at treatment start. Low albumin levels, similar to
other biomarkers, reﬂect the severity of the tissue damage
resulting fromGVHD. A low albumin level has been shown to
predict a poor response to ﬁrst-line therapy for GVHD [4,15].
Therefore, and with our ﬁndings, it seems plausible that
these biomarkers can be used in the steroid-refractory
setting as well. Liver GVHD has not been reported before as
a distinct risk factor for treatment outcome in GVHD.
Nevertheless, liver involvement seemed to provide prog-
nostic information in our cohort. This can be explained by the
fact that all patients suffered from GI GVHD, and, presum-
ably, simultaneous involvement of another visceral organ
entails less chances of response to treatment. The reasonwhy
post-DLI GVHD was associated with a poor prognosis is,
however, less clear. There are limited data on the
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although treatment responses are generally reported to be
good and death occurring from GVHD post-DLI is rare [16].
However, no data exist on the speciﬁc setting of steroid-
refractory GVHD post-DLI. Hence, our observation must be
interpreted with care, especially because it concerned a
small patient group and the observed poor prognosis might
be well related to chance. Nevertheless, currently no data
suggest that GVHD post-DLI should be managed differently
[17].
The overall response rate we achieved with combined
inolimomab and etanercept is similar to those reported for
other therapies used for refractory aGVHD [3]. Although some
strategies seem to result in higher response rates, none of
them has really resulted in acceptable OS rates. Promising
therapies, such as extracorporeal photopheresis and mesen-
chymal stem cells, have shown better results, but these seem
to be inﬂuenced by the inclusion of more patients with grade
II refractory aGVHD or inclusion of children who might
respond differently from adults to aGVHD therapy [18,19].
There is clearly a need for better designed prospective
studies if we want to make progress in the management of
steroid-refractory aGVHD [20]. Because the OS in refractory
aGVHD remains poor, it might be important to prevent re-
fractory disease by intensifying ﬁrst-line therapy with com-
bination therapy or by using preemptive strategies in those
at high risk of developing aGVHD. Intensifying therapy in an
earlier phase and response evaluation after 3 instead of
5 days of steroid use could also be possibilities. However,
these strategies come at a price, namely infectious compli-
cations and risk of overtreatment with an increased proba-
bility of relapse. Consequently, a more risk-adapted approach
might prove of more value when identifying patients who
will not respond adequately to corticosteroid therapy,
assuming that risk factors and biomarkers can be identiﬁed
and validated [21]. Another approach that might be explored
is trying to induce a remission of GVHD by intensive but
temporary immunosuppressive therapy followed by rapid
tapering in case of response complemented by strategies to
hasten the healing process of damaged tissues, for instance,
with epithelial growth factors. This will prevent the need for
long-term high-dose immunosuppressive therapy and lower
the risk for infections and relapse of the hematologic
malignancy.
In conclusion, the use of combination therapy consisting
of inolimomab and etanercept as second-line treatment for
severe steroid-refractory aGVHD resulted in an acceptable
response rate but nevertheless lacked any beneﬁt with
regards to long-term survival. Therefore, there remainsmuch
room for improvements, which can only be achieved by
prospective multicenter studies, which necessitates intense
cooperation between SCT centers.
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